Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and vorinos...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news
Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.
EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.
MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and v...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news
Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101
< p > < p class="stdBody" > < strong > Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP & trade; biomarker for Mundipharma EDO & rsquo;s lead compound EDO-S101 for the treatment of cancer. < /strong > < /p > < p class="stdBody" > < b style="line-height: 1.6;" > EDO-S101 is a first in class fusion molecule that combines two drugs & #39; mechanism of action in the cancer cell in order to increase the effect of treatment. < /b > < /p > < p class="stdBody" > < o:p > < /o:p > < /p > < ...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news
Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP ™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and vorinos...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news
Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101
Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.
EDO-S101 is a first in class fusion molecule that combines two drugs' mechanism of action in the cancer cell in order to increase the effect of treatment.
MPI's specific DRP™ multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and v...
Source: Kidney Cancer Association - February 10, 2016 Category: Urology & Nephrology Source Type: news
Bendeka (Bendamustine Hydrochloride Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 16, 2015 Category: Drugs & Pharmacology Source Type: news
Teva, Eagle Cancer Drug Gets FDA Nod
FDA has approved BENDEKA injection -- a liquid, low-volume, 10-minute infusion formulation of bendamustine (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2015 Category: Pharmaceuticals Source Type: news
Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'
In chronic lymphocytic leukemia, idelalisib combined with bendamustine and rituximab improved progression-free and overall survival compared with the standard two-drug combination. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Teva gets FDA approval for cancer drug
(Reuters) - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine. (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Phase III HELIOS (CLL3001) trial assessed the safety and efficacy of IMBRUVICA plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
NORTH CHICAGO, Ill., Nov. 13, 2015 -- (Healthc... Biopharmaceuticals, Oncology, FDAAbbVie, IMBRUVICA, ibrutinib, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2015 Category: Pharmaceuticals Source Type: news
RBAC500 safe, effective for elderly patients with mantle cell lymphoma
Reducing the dose of cytarabine from 800 mg/m2 to 500 mg/m2 allowed a regimen of rituximab, bendamustine, and cytarabine to be safely administered as first-line therapy to elderly patients who had mantle cell lymphoma and were not candidates for autologous stem cell... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 8, 2015 Category: Dermatology Source Type: news
Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening
Roche today announced results from the Phase III GADOLIN study showing that Gazyva/Gazyvaro (obinutuzumab) plus bendamustine followed by Gazyva/Gazyvaro alone provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL) that is refractory to MabThera/Rituxan (rituximab)-based treatment (Source: Roche Media News)
Source: Roche Media News - May 30, 2015 Category: Pharmaceuticals Source Type: news
Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening
Roche today announced results from the Phase III GADOLIN study showing that Gazyva/Gazyvaro (obinutuzumab) plus bendamustine followed by Gazyva/Gazyvaro alone provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL) that is refractory to MabThera/Rituxan (rituximab)-based treatment (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news
Targeted Drug with Chemotherapy Combo Offers Longer Life to Patients with B-cell Cancers
CHICAGO — Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 30, 2015 Category: Databases & Libraries Source Type: news
